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PURPOSE. To identify microRNAs (miRNAs) involved in primary open-angle glaucoma (POAG),
using genetic data. MiRNAs are small noncoding RNAs that posttranscriptionally regulate gene
expression. Genetic variants in miRNAs or miRNA-binding sites within gene 30-untranslated
regions (30UTRs) are expected to affect miRNA function and contribute to disease risk.
METHODS. Data from the recent genome-wide association studies on intraocular pressure,
vertical cup-to-disc ratio (VCDR), cupa area and disc area were used to investigate the
association of miRNAs with POAG endophenotypes. Putative targets of the associated miRNAs
were studied according to their association with POAG and tested in cell line by transfection
experiments for regulation by the miRNAs.
RESULTS. Of 411 miRNA variants, rs12803915:A/G in the terminal loop of pre–miR-612 and
rs2273626:A/C in the seed sequence of miR-4707 were significantly associated with VCDR
and cup area (P values < 1.2 3 104). The first variant is demonstrated to increase the miR-
612 expression. We showed that the second variant does not affect the miR-4707 biogenesis,
but reduces the binding of miR-4707-3p to CARD10, a gene known to be involved in
glaucoma. Moreover, of 72,052 miRNA-binding-site variants, 47 were significantly associated
with four POAG endophenotypes (P value < 6.9 3 106). Of these, we highlighted 10
variants that are more likely to affect miRNA-mediated gene regulation in POAG. These
include rs3217992 and rs1063192, which have been shown experimentally to affect miR-138-
3p– and miR-323b-5p–mediated regulation of CDKN2B.
CONCLUSIONS. We identified a number of miRNAs that are associated with POAG
endophenotypes. The identified miRNAs and their target genes are candidates for future
studies on miRNA-related therapies for POAG.
Keywords: primary open-angle glaucoma (POAG), microRNA, genetic variant, GWAS
Primary open-angle glaucoma (POAG), the most commonoptic neuropathy, is the leading cause of irreversible
blindness, affecting approximately 60 million individuals
worldwide.1,2 The disease is characterized by progressive loss
of retinal ganglion cells and optic nerve degeneration that can
be secondary to elevated intraocular pressure (IOP).3 The optic
nerve damage is characterized by an increase in cup size, which
is the central area of the optic disc. Cup enlargement can be
measured by the vertical cup-to-disc ratio (VCDR), comparing
the vertical diameter of the cup with vertical diameter of the
total optic disc.4 The VCDR ranges from 0 to 1; a ratio above 0.7
or an asymmetry between eyes above 0.2 is considered as
suspect for glaucoma in the clinical setting.5 POAG is presumed
to be a complex progressive neurodegenerative disorder caused
by multiple genetic as well as environmental factors.2 Previous
genome-wide association studies (GWASs) have revealed a
number of susceptibility loci for POAG by studying the disease
directly or its endophenotypes including IOP and optic disc
parameters (VCDR, cup area, and disc area).5,6 Most of the
associated variants identified by GWASs are located in
noncoding regions of the genome and their mechanistic
contributions to POAG and its endophenotypes remain poorly
understood.5,6
MicroRNAs (miRNAs) are small noncoding RNAs, consisting
of 19 to 22 nucleotides, that posttranscriptionally regulate gene
expression.7 There are strong indications that miRNAs play
important roles in the pathogenesis of POAG.8–11 For example,
miR-29b and miR-24 are involved in gene regulation in
trabecular meshwork cells.12 Moreover, the miRNA expression
levels have been linked to maintaining the balance of the
aqueous humor, the change in the trabecular meshwork, and
the apoptosis of the retinal ganglion cells.13–15 A number of
miRNAs (e.g., miR-200c, miR-204, miR-183, and miR-182) are
also reported as potential diagnostic biomarkers or therapeutic
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targets for glaucoma.9,16 The biogenesis of miRNAs is a
multistep coordinated process.17,18 In the nucleus, miRNA
genes are initially transcribed as long primary transcripts.
Further processing and cleavage by the RNase Drosha and
Dicer enzymes generate mature miRNAs.17,18 The mature
miRNAs are subsequently incorporated into the RNA-induced
silencing complex (RISC) to interact with the 30-untranslated
region (30UTR) of target mRNAs, resulting in mRNA degrada-
tion or translational repression.7,18 Genetic variants in miRNA-
encoding sequences can have profound effects on miRNA
biogenesis and function.19,20 In addition, polymorphisms
located in miRNA-binding sites within the 30UTR of target
genes are expected to affect miRNA-mediated gene regula-
tion.20,21 Previous studies19,21–23 have shown that such miRNA-
related variants contribute to complex disease risk; a candidate
variant association study24 has also recently reported the
association between genetic variation in miR-182 and POAG. In
this study, we applied an in silico study on the existing GWAS
of IOP and optic disc parameters5 and performed in vitro
experiments to identify miRNAs and target genes that may play
a role in POAG.
METHODS
Genome-Wide Association Studies on Glaucoma
Endophenotypes
To examine the association of miRNA-related genetic variants
with POAG endophenotypes, we used data from the recent
GWAS on glaucoma endophenotypes provided by the Interna-
tional Glaucoma Genetics Consortium (IGGC).5 Characteristics
of the IGGC have been described elsewhere.5 In brief, the
IGGC has conducted genome-wide association meta-analyses
on four glaucoma endophenotypes including IOP (n¼ 37,930
individuals), VCDR (n ¼ 23,899 individuals), cup area (n ¼
22,489 individuals), and disc area (n¼ 22,504 individuals). The
IGGC, using imputation to the 1000 Genomes (1000G)
reference panel, has tested the association of approximately
8 million single-nucleotide polymorphisms (SNPs) with minor
allele frequency (MAF) > 0.01 with glaucoma endopheno-
types. The summary association statistics for these phenotypes
are available in the public domain (http://www.dropbox.com/
sh/3j2h9qdbzjwvaj1/AABFD1eyNetiF63I5bQooYura?dl¼0).
Genetic Variants Located in miRNAs and miRNA-
Binding Sites
A total of 2420 genetic variants located in miRNA-encoding
sequences were retrieved from miRNASNP v2 (database update
April 2015)25 and literature review (searching for miRNA
genetic variants in PubMed). These include variants in
precursor miRNAs (60–80 nucleotides [nt]), mature miRNA
sequences (19–22 nt), and miRNA seed regions (nucleotides 2–
8 from the 50-end of a mature miRNA, which is defined as the
most crucial part of an miRNA for target recognition and has to
be perfectly complementary to the binding site of a target
mRNA). Of 2420 miRNA variants, 411 (in 332 miRNAs) were
available in the GWAS data of glaucoma endophenotypes and
were selected for association analysis. These variants include
283 in pre-miRNA loci, 87 in mature miRNA sequences, and 41
in miRNA seed regions. Moreover, we extracted almost
401,000 genetic variants (including SNPs and INDELs) in
miRNA-binding sites within the gene 3 0UTRs by using
PolymiRTS v3 (database update October 2014).26 Of these,
72,052 miRNA-binding-site variants were available in the GWAS
data of glaucoma endophenotypes and were included for
association analysis. The Bonferroni correction was used to
adjust the P value for multiple comparisons. To this end, we
divided the critical P value (a¼ 0.05) by the number of genetic
variants in each group (miRNAs and miRNA-binding sites). As
we studied 411 variants in miRNAs, the significance threshold
was set on 1.223 104 (0.05/411) for miRNA genetic variants.
Likewise, the significance threshold for genetic variants in
miRNA-binding sites was set on 6.94 3 107 (0.05/72,052), as
we studied 72,052 variants in this group (Fig. 1). Regional
association plots showing the association of miRNA-related
variants with the studied phenotypes were made by using
LocusZoom.27
The Effect of Variants on the miRNA Secondary
Structure and Expression
The secondary structure of pre-miRNA is critical for the miRNA
biogenesis.28 The Vienna RNAfold algorithm (ViennaRNA
package 2.0) was used to predict the impact of variants in
miRNAs on the hairpin stem-loop structure of pre-miRNAs.29
This program calculates the changes in minimum free energy
(MFE) of the thermodynamic ensemble of the hairpin structure
of miRNA (wild type and mutant). Next, to test the functional
impact of an miRNA variant on the expression of the mature
miRNA, we cloned the pre-miRNA sequence containing either
the major or minor allele behind the gene encoding green
fluorescent protein (GFP) in the expression plasmid MSCV-BC
(Murine Stem Cell Virus-Bar Coded), resulting in GFP-miRNA
fusion transcripts as described previously.30 For cloning
purposes, the restriction enzyme sites XhoI and EcoRI were
inserted in forward and reverse primers, respectively. The
primers are listed in Supplementary Table S1. We used Sanger
sequencing to validate the inserts of all constructs. HEK293
cells were plated at a density of 53 105 cells per well in a six-
well plate and were cultured in 2 mL Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine serum
and 100 units/mL penicillin/streptomycin in a 378C incubator
with 5% CO2. The next day, cells were transiently transfected
with 1 lg GFP-miRNA constructs containing either the major
or minor allele by using LipofectamineR RNAiMAX (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instruc-
tions. After 48 hours, total RNA was isolated with the TRIZOL
reagent (Invitrogen) according to the manufacturer’s protocols.
The concentration and purity of RNA samples were deter-
mined with a NanoDrop ND-1000 spectrophotometer (Nano-
Drop, Wilmington, DE, USA). TaqMan Assays (Applied
Biosystems, Foster City, CA, USA) were used to measure the
expression levels of GFP and miRNA by quantitative RT-PCR.
The expression levels of mutant and wild-type miRNA relative
to GFP were calculated as previously described.30 RNU6B was
used as an internal loading control for miRNA expression. All
experiments were performed in triplicate and repeated at least
three times.
Association of miRNA Target Genes With Glaucoma
Endophenotypes
The biological role of miRNAs is dictated through regulating
expression of their target mRNAs. We aimed to identify target
genes that may mediate the downstream effects of the
associated miRNAs in relation to POAG endophenotypes. Since
such genes should be also associated with the studied
phenotypes, we used the GWAS data in a candidate gene
approach and searched among the putative target genes of an
miRNA for those that were associated with POAG endopheno-
types. To this end, we extracted the miRNA putative targets by
using two commonly used online databases: TargetScan v7.0
(total contextþþ score > 0.1)31 and miRDB.32 TargetScan
(http://www.TargetScan.org/; in the public domain) predicts
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biological targets of miRNAs by searching for the presence of
conserved sites that match the seed region of each miRNA. The
predictions in this database are ranked by the predicted
efficacy of targeting as calculated by using cumulative
contextþþ scores of the sites by considering several features
to predict the most effective target mRNAs.31 The targets in
miRDB (http://mirdb.org//; in the public domain) were
predicted by a bioinformatics tool, which was developed by
analyzing thousands of miRNA–target interactions from high-
throughput sequencing experiments.32 The GWAS data from
glaucoma endophenotypes were used to examine the associ-
ation of genetic variants in the predicted miRNA target genes
with the phenotype of interest.5 The Bonferroni correction
was used to calculate the significance level based on the
number of tested genetic variants in all predicted target genes
of each miRNA.
Interaction Analysis Between an miRNA and Its
Target Genes Using the Rotterdam Study Data
The external validity of association between an miRNA variant
and associated phenotype may improve when the variant
affects the miRNA target genes involved in the phenotype. We
thus tested the interaction between associated miRNA variants
and the most significant variant in their related target genes in
relation to POAG endophenotype, using the Rotterdam Study
data. To examine the interaction, we introduced the statistical
product of miRNA variant and target gene variant in the logistic
regression model, adjusted for age and sex: POAG endophe-
notype ~ age þ sex þmiRNA SNP þ top SNP in target gene þ
(miRNA SNP 3 top SNP in target gene). The design of the
Rotterdam Study has been described in detail elsewhere.33 The
baseline characteristics of the subjects are shown in Supple-
mentary Table S2.
Luciferase Reporter Assays
A luciferase reporter assay system was used to examine the
interaction between an miRNA and the 30UTR of its putative
target gene. In addition, this experiment was used to
determine the impact of candidate variant on the miRNA–
target gene interaction. To this end, primers were designed to
amplify the 30UTR sequence of the miRNA target gene and
included restriction enzyme sites XbaI for the forward primer
and ApaI for the reverse. The 30UTR sequences containing
putative binding site (wild type and mutated) of the miRNA
were amplified and cloned into the pGL3 Luciferase reporter
vector (Promega, Madison, WI, USA) downstream of the
Luciferase open reading frame.30 All the primers are shown
in Supplementary Table S3. The inserts of all constructs were
FIGURE 1. A schematic workflow of our analyses to identify genetic variants in miRNAs as well as in miRNA-binding sites within gene 30UTRs that
are associated with four POAG endophenotypes.
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confirmed by Sanger sequencing. HEK293 cells (n ¼ 10,000)
were plated into 96-well plates and cotransfected with 1 lg
pGL3 containing the 30UTR with either the major or minor
allele, miRNA mimic (mirVana Mimics; Thermo Fischer
Scientific, Waltham, MA, USA), and a plasmid expressing the
Renilla luciferase that served as transfection control, with
Lipofectamine RNAiMAX (Invitrogen). Luciferase activity was
measured with the Dual-Glo Luciferase Assay System according
to manufacturer’s protocol (Promega). Renilla activity was
used for normalization of the data. All experiments were
performed in triplicate and repeated in three independent
experiments.
Functional Annotation of miRNA-Binding-Site
Variants Associated With Glaucoma
Endophenotypes
Specific criteria have been suggested to establish whether
3 0UTR variants located in miRNA-binding sites may affect
miRNA-mediated gene regulation.20,21 These include associa-
tion between the variant and the phenotype of interest,
expression of hosting gene and related miRNA in a relevant
tissue, and an allele-specific regulation of the target transcript
by miRNA.20,21 These criteria were used to prioritize the
miRNA-binding-site variants that are more likely to be
functional. We first retrieved proxy SNPs in high linkage
disequilibrium (LD) (R2 threshold > 0.8, limit distance 100
kb, and population panel CEU) with the binding-site variants
and checked their effects on protein structure, gene
regulation, and splicing by using the HaploRegv4.1 (http://
www.broadinstitute.org/mammals/haploreg/haploreg.php; in
the public domain). The HaploReg 4.1 was also used to
evaluate the functional potential of the LD variants associated
with glaucoma endophenotypes. To scan the correlation
between the identified variants and expression levels of the
host transcripts, we used expression quantitative trait loci
(cis-eQTL) data from the GTExV6 (http://www.gtexportal.
org/home/; in the public domain) and Genenetwork (http://
genenetwork.nl/bloodeqtlbrowser/; in the public domain). To
check whether miRNAs in our collection are expressed in
ocular tissues, two online databases were screened, miReti-
na34 and HMDD.35 Moreover, we used expression data from
previous miRNA profiling studies in human ocular tissues,
including ciliary body, cornea, and trabecular meshwork and
aqueous humor.13–15 Other miRNA information, including
miRNA conservation in different species, was obtained from
miRBase (release 20).36 In addition, the Ocular Tissue
Database (https://genome.uiowa.edu/otdb/; in the public
domain) was used to examine the expression of the identified
miRNA target genes across the eye tissues. Supplementary
Table S4 shows a list of web tools and databases that we used
for our analyses.
RESULTS
Two miRNA Variants Were Associated With POAG
Endophenotypes
We examined the association of 411 miRNA variants (in 332
miRNA genes) with IOP, VCDR, cup area, and disc area (Fig. 1).
Two miRNA variants passed the Bonferroni-corrected signifi-
cance threshold of 1.22 3 104 (0.05/411). These variants
include rs12803915:A/G (Chr11:65444508) in the terminal
loop of pre–miR-612 sequence associated with VCDR (P value
¼ 4.63 109, b¼0.009) and cup area (P value¼ 1.23 107, b
¼0.014), and rs2273626:A/C (Chr14:22956973) in the seed
sequence of miR-4707 associated with VCDR (P value¼ 9.5 3
105, b ¼ 0.005) and cup area (P value ¼ 9.9 3 105, b ¼
0.008) (Table 1). No miRNA variants were significantly
associated with IOP and disc area. Supplementary Table S5
shows genetic variants in miRNAs that are nominally associated
(P value < 0.05) with POAG endophenotypes.
The Impact of Variants on the miRNA Secondary
Structure and Expression
The impact of rs12803915 and rs2273626 on the miRNA
biogenesis was measured by performing structural analysis of
the miRNA hairpin, using Vienna RNAfold algorithm.29 We
observed 0.8 kcal/mol difference in MFE of the thermodynamic
ensemble of the miRNA hairpin structure for pre–miR-612 and
5.8 kcal/mol difference for pre–miR-4707, suggesting that the
variants may affect their miRNA production (Supplementary
Fig. S1). Rs12803915 (minor allele A) in pre–miR-612 has been
demonstrated previously to increase expression of the mature
miRNA in vitro.37 Additionally, we cloned the miR-4707
precursor with either the rs2273626 major allele G or the
minor allele T behind GFP in the pMSCV-BC vector. HEK293
cells were transfected with the vectors expressing transcripts
with GFP and pre-miRNA. We observed no significant
difference between expression levels of mature miR-4707 in
cells transfected with the pre-miRNA sequence containing the
major and the minor allele (Fig. 2A). This indicates that the
effect of rs2273626 on the miR-4707 biogenesis is minor and
not detectable with this experimental setup.
TABLE 1. Association of Top miRNA Variants With POAG Endophenotypes
Phenotype SNP ID Chr Position A1/A2 MAF miRNA ID SNP Position 4 MFE P Value b SE
VCDR rs12803915 11 65444508 A/G 0.14 miR-612 Stem region 0.8 4.6 3 109 0.009 0.0015
rs2273626 14 22956973 A/C 0.48 miR-4707 Seed 5.8 9.5 3 105 0.005 0.0012
rs58834075 14 101066756 C/A 0.09 miR-656 Loop 0.6 2.2 3 103 0.014 0.0047
Cup area rs12803915 11 65444508 A/G 0.14 miR-612 Stem region 0.8 1.2 3 107 0.014 0.0028
rs2273626 14 22956973 A/C 0.48 miR-4707 Seed 5.8 9.9 3 105 0.008 0.0021
rs13299349 9 18573362 A/G 0.22 miR-3152 Mature miR 4.9 1.9 3 104 0.009 0.0024
Disc area rs76118570 21 23079302 A/T 0.02 miR-6130 Pre-miRNA 0.0 5.4 3 104 0.288 0.0831
rs72631820 7 1022963 A/G 0.02 miR-339 Mature miR 0.6 3.2 3 103 0.143 0.0485
rs12512664 4 7461769 A/G 0.61 miR-4274 Pre-miRNA 0.3 4.6 3 103 0.013 0.005
IOP rs2289030 12 94834510 C/G 0.11 miR-492 Pre-miRNA 1.7 4.2 3 103 0.12 0.042
rs515924 11 74399308 A/G 0.18 miR-548al Seed 0.0 4.5 3 103 0.086 0.03
rs9877402 3 121049645 A/G 0.13 miR-5682 Pre-miRNA 1.4 5.0 3 103 0.156 0.056
Shown are top three miRNA variants with the most significant association with each of the POAG endophenotypes. Two variants that pass the
significant threshold (P value < 1.223 104) are shown in bold. A, allele; Chr, chromosome; SE, standard error; 4 MFE, change in minimum free energy.
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Target Genes of miR-612 and miR-4707 Associated
With VCDR and Cup Area
To identify target genes that may mediate the downstream
effect of miR-612 and miR-4707 in relation to VCDR and cup
area, we studied the association of their putative target genes
with these phenotypes, using the GWAS data.5 Supplementa-
ry Table S6 displays four predicted target genes of miR-612
and eight predicted target genes of miR-4707 that are
associated with VCDR and cup area. Using data from the
Ocular Tissue Database, we showed that these associated
target genes are expressed in the eye tissues (Supplementary
Table S7). We further tested the interaction between the
identified miRNA variants and the top variant in their
highlighted predicted target genes (associated with glaucoma
endophenotypes and expressed in the eye), using the
Rotterdam Study data. This analysis showed a significant
interaction (P value¼ 0.028) between rs2273626 in miR-4707
and the top variant (rs6000755) in CARD10 (Supplementary
Table S8). Luciferase reporter assays then demonstrated that
miR-4707-3p downregulates the expression of CARD10 (Fig.
2B). Our experiments further showed a significant difference
in luciferase activity of the CARD10 3 0UTR construct in the
presence of miR-4707-3p containing the major allele G,
compared to the minor allele T at rs2273626 site (Fig. 2B).
These data indicate that the minor allele G decreases the
binding of miR-4707-3p to CARD10.
Multiple miRNA-Binding-Site SNPs Were Associated
With POAG Endophenotypes
In the second part of our study, we examined the associations
of 72,052 miRNA-binding-site SNPs (available in the GWAS
data38) with POAG endophenotypes (Supplementary Fig. S2).
Of these, 47 SNPs (located in the 30UTR of 21 genes) passed
the Bonferroni-corrected significance threshold of 6.943 107,
which are associated with one or more of the POAG
endophenotypes. These SNPs are predicted to affect the
putative interaction between their host genes and a number
of miRNAs that are shown in Supplementary Table S9. To
highlight the binding-site variants that are more likely to affect
miRNA-mediated gene regulation, we prioritized them on the
basis of various criteria (e.g., the strength of association, LD
pattern, eQTL data, coexpression of miRNA and target gene in
relevant tissue). Haploreg v4.1 data, we found showed that
many of the binding-site SNPs (n ¼ 37) have no nonsynon-
FIGURE 2. The impact of SNP rs2273626 in the seed sequence of miR-4707 on miRNA production and targeting. (A) The figure shows the predicted
hairpin structure of miR-4707 containing rs2273626, which was associated with VCDR and cup area. The mature miRNA sequences (3p and 5p) are
shown in red and the position of variants is depicted by an arrow. To examine the effect of rs2273626 on the miR-4707 expression level, HEK293
cells were transfected with GFP-miRNA transcripts containing either the minor allele T or the major allele G. The levels of mature miRNA relative to
GFP transcript levels were calculated. (B) Luciferase reporter assays indicating miR-4707-3p–mediated repression of CARD10. HEK293 cells were
cotransfected with CARD10 30UTR luciferase reporter vector and GFP-miRNA transcripts containing either the minor allele T or the major allele G.
This experiment indicates a significant difference (P¼0.04) between the relative luciferase activity of the CARD10 30UTR construct in the presence
of miR-4707-3p containing the major allele and the minor allele. Our results suggest that rs2273626 diminishes the regulatory interaction between
miR-4707-3p and CARD10, resulting in increased CARD10 levels. All experiments were performed in triplicates and repeated at least three times.
Error bars represent standard deviation (SD). NS, nonsignificant.
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ymous proxy variants in strong LD (R2 > 0.8) (Supplementary
Table S10). The cis-eQTL data further showed that 33 of the
SNPs are correlated with the expression levels of their genes in
different tissues (Supplementary Table S10). The Ocular Tissue
Database showed that all 21 hosting genes are expressed in the
eye (Supplementary Table S11). Using the miRNA expression
databases, we found evidence for the expression of several
miRNAs in our collection in the eye (Supplementary Table
S12). After prioritizing the 47 associated SNPs, based on their
functional score, we highlighted 10 variants that are more
likely to affect miRNA-mediated gene regulation in POAG
(Table 2; Supplementary Fig. S3). These include two SNPs in
the 30UTR of CDKN2B, rs3217992 and rs1063192, which have
been demonstrated previously to affect miR-138-3p– and miR-
323b-5p–mediated regulation of CDKN2B.21
DISCUSSION
In this study, we performed a genome-wide scan to identify
miRNAs associated with POAG endophenotypes, using genetic
data. We found genetic variants in the miR-612 precursor and
in the miR-4707 seed region significantly associated with VCDR
and cup area. The variant in miR-612 has been previously
demonstrated to increase the miRNA expression.37 We showed
that the variant in miR-4707 does not influence the miRNA
expression, but affects the binding of miR-4707 to one of its
glaucoma-associated target genes, CARD10. Moreover, we
identified 47 SNPs in miRNA-binding sites (within the 30UTR
of 21 genes) that are significantly associated with POAG
endophenotypes. After prioritization, we highlighted the
30UTR variants that are more likely to affect miRNA-mediated
gene regulation in POAG.
Several studies8,9,15 have shown previously the contribution
of miRNAs to the pathophysiology of POAG. However, these
studies are mainly focused on differentially expressed miRNAs
indentified by miRNA profiling in a small number of samples,
which makes it difficult to interpret their results to the general
population. In addition, miRNA profiling studies are sometimes
subject to confounding bias or reverse causation, and cannot
provide evidence for a causal role of the identified miRNAs in
relation to a disease. Here, we used a genetic approach that is
proven to be efficient and successful for identification of
miRNAs involved in complex traits.19–23 In this approach, the
starting point is a linkage between miRNA variants and the trait
of interest. The main advantage of the genetic approach
compared to miRNA expression profiling is that when a variant
is associated with disease risk, it supports the idea that the
miRNA may have a primary effect in the disease pathogenesis.
Given that genetic variants are randomly inherited, it is unlikely
that other extrinsic factors (e.g., lifestyle) are associated with
them. Moreover, as the DNA sequence is constant over the life
course, reverse causation is also refuted. Another advantage of
the genetic approach is that diseases with no accessible
affected tissues (e.g., eye tissue of glaucoma patients) can still
be studied, since genomic DNA is available from other
accessible tissues such as blood. The main limitation of the
genetic approach is that it is restricted to miRNAs with genetic
variants available in the GWAS data. Therefore, both genetic
and miRNA profiling approaches are valuable and can work
complementarily to analyze different aspects of the role of
miRNAs in disease pathogenesis. The genetic approach
indicates whether miRNAs are potentially casual or risk factors
for a disease and the miRNA profiling approach demonstrates
whether the expression of the disease-associated miRNAs is
altered in the affected tissue.
We found two variants in the precursor and seed region of
miRNAs significantly associated with POAG endophenotypes.T
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The first variant is rs12803915 located in miR-612. The GWAS
data show that the variant minor allele A is associated with
decreased VCDR and cup area.5 The variant minor allele has
been demonstrated previously to increase the expression of
mature miR-612 in vitro.37 The location of variant in the
terminal loop of miR-612 possibly improves the pre-miRNA
processing, and consequently increases the miRNA expres-
sion.39–42 Next, we highlighted four putative miR-612 targets
(USH2A, FAM101A, JRK, and SIX4) that are also associated
with VCDR and cup area and are expressed in the eye. These
target genes might mediate the downstream effect of miR-612
in POAG. Together, our results suggest a protective role for
miR-612 in relation to POAG. Future experimental studies are
needed to further elucidate the role of miR-612 and its
highlighted target genes in the pathogenesis of POAG.
The second associated variant is rs2273626 located in the
seed sequence of miR-4707, an miRNA that is shown to be
expressed in aqueous humor of glaucoma patients.43 The variant
minor allele A was negatively associated with VCDR and cup
area in the GWAS data.5 A polymorphism in an miRNA seed
sequence is expected to strongly influence the miRNA activity
and possibly risk of disease.20,44 We tested the two mechanisms
through which a seed sequence variant may affect miR-4707
function. Our results showed that rs2273626 has no significant
effect on the miRNA expression levels. However, the variant
reduces the interaction between miR-4707-3p and CARD10,
presumably resulting in higher CARD10 levels. The CARD10
gene is reported in several GWAS to be associated with
glaucoma.6,45–47 The activity of CARD10 has been suggested
to have a neuroprotective role in glaucomatous optic neurop-
athy.45 POAG is a disease of enhanced retinal ganglion cell
apoptosis.48 It has been postulated that CARD10 controls optic
disc area possibly through ganglion axonal survival via the
activation of the NFjB signaling pathway.46,49 Overexpression of
CARD10 has been shown to be related with increased cell
survival and proliferation.50,51 Conversely, homozygous knock-
out of CARD10 in a mouse model can cause nonviability
through neural tube defects.52 CARD10 has been also shown to
be required in neural crest cell survival through G protein–
coupled receptor induction of NFjB activation.52 Retinal
ganglion cell damage from NFjB is likely to be due to glial
cell activation and IL-1b secretion.53 Given the intimate and
complex relationship between CARD10, NFjB, and apoptosis,47
it is biologically plausible that lower levels of CARD10 result in
increased retinal ganglion cell apoptosis. In our study, the
negative association between the miR-4707 variant and POAG
may be explained in part by higher CARD10 expression due to
the disruption of miR-4707–mediated gene regulation.
In the second part of this study, we investigated the
association of miRNA-binding-site variants with POAG endophe-
notypes and identified 47 associated SNPs. GWASs are based on
tagging variants that are in high LD with functional variant(s) in
the region; it is thus challenging to determine the exact
localization of the variants that cause the associations. Here
we prioritized the 47 associated SNPs on the basis of a set of
predefined criteria (e.g., the strength of association, LD
evaluation, eQTL analysis, coexpression of the miRNA and the
target gene in relevant tissue).20,21 We highlighted 10 of the
variants that are more likely to affect the putative miRNA-
mediated regulation. Among them, rs1063192 and rs3217992
have been shown previously to affect the miRNA–mRNA
interaction in vitro.21,54 These two SNPs reside in the 30UTR
of CDKN2B and are not in strong LD (R2 > 0.8) with any other
known CDKN2B variants. The CDKN2B gene encodes a cyclin-
dependent kinase inhibitor and with its antisense (CDKN2B-
AS1) lies in a well-known glaucoma-associated locus on
Chr.9p21.5,6 The minor allele (G) at rs1063192 site is predicted
to create a binding site for miR-323b-5p and the rs3217992
minor allele (T) is expected to disrupt the existing binding site
of miR-138-2-3p within the 30UTR of CDKN2B. Horswell et al.54
have shown that these miRNAs control both CDKNB2 mRNA
and protein levels. Moreover, they have shown the correlation of
rs1063192 minor allele with lower CDKN2B mRNA levels
(improving the miR-323b-5p–mediated regulation) and con-
versely, the correlation of rs3217992 minor allele with higher
CDKN2B mRNA levels (disrupting the miR-138-3p–mediated
regulation) in adipose tissue.54 Although the impact of these
variants on the CDKN2B expression needs to be demonstrated
in the ocular tissues, the functional consequences of both
variants on the miRNA-binding sites have been confirmed by
Luciferase reporter assays in cell lines.21,54 Thus, an allelic-
specific regulation of CDKN2B by miR-232b-5p and miR-138-2-
3p may be considered as a potential mechanism, at least in part,
to explain the association between CDKN2B (rs1063192 and
rs3217992) and POAG.
In addition to the two experimentally validated variants in
the 30UTR of CDKN2B, we found several other 30UTR variants
associated with POAG endophenotypes that are located in
miRNA-binding sites and are one of the top variants in their loci
with no nonsynonymous proxy in high LD (R2 > 0.8). These
variants have the potential to be functional variants in their loci
by affecting miRNA-mediated gene regulations and warrant
further investigations. For example, the minor allele of
rs1052990 in the 30UTR of CAV2, a known gene for glaucoma,
is predicted to disrupt the predicted binding site of miR-224-5p
and increase the transcript levels of CAV2. The association of
the rs1052990 minor allele with increased expression levels of
CAV2 has been reported previously.55 In addition, both miR-
224-5p and CAV2 are expressed in the eye.56,57 These data may
suggest an allele-specific regulation of CAV2 by miR-224-5p as a
functional mechanism underlying the observed GWAS associ-
ation.
Although we believe our results are reliable, there are
certain limitations that need to be considered in interpreting of
our results. First, the reported miRNA–target interactions are
predicted from in silico approach and need to be validated by
experimental studies. Second, we used eQTL data from various
tissues, but not eye tissue, to check the association between
the identified 30UTR variants and the expression of hosting
genes. As gene expression and eQTL are tissue specific, in an
optimal setting one should examine the associations in the
ocular tissues. Finally, we were not able to perform the
functional experiments in a relevant cell line for glaucoma
disease, owing to slow growth rate and low transfection
efficiency of retinal ganglion cells in culture. However, to gain
insights into the impact of the identified variant on miR-4707,
we performed our experiments with HEK293 cells, a
commonly used cell line in this type of studies.
CONCLUSIONS
We systematically investigated the association of miRNA-related
genetic variants with four POAG endophenotypes. We found
variants in the miR-612 precursor and in the miR-4707 seed
region that are significantly associated with VCDR and cup
area. Our results showed that the minor allele of these variants
may alter expression or targeting of the miRNAs. Further, we
highlighted a number of 30UTR variants associated with POAG
endophenotypes that are located in the predicted miRNA-
binding sites and may affect miRNA-mediated gene regulation
in POAG. The identified miRNAs and target genes are
candidates for future studies to determine their roles in the
pathophysiology of POAG and their therapeutic potentials for
glaucoma.
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